Mirati Therapeutics, Inc. (MRTX): Price and Financial Metrics

Mirati Therapeutics, Inc. (MRTX): $58.70

0.10 (-0.17%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

D

Add MRTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#304 of 359

in industry

MRTX Price/Volume Stats

Current price $58.70 52-week high $64.41
Prev. close $58.80 52-week low $27.30
Day low $58.54 Volume 20,994,400
Day high $58.99 Avg. volume 2,758,857
50-day MA $57.69 Dividend yield N/A
200-day MA $45.47 Market Cap 4.12B

MRTX Stock Price Chart Interactive Chart >

MRTX POWR Grades

  • Growth is the dimension where MRTX ranks best; there it ranks ahead of 54.59% of US stocks.
  • MRTX's strongest trending metric is Quality; it's been moving down over the last 95 days.
  • MRTX's current lowest rank is in the Stability metric (where it is better than 2.97% of US stocks).

MRTX Stock Summary

  • MRTX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 346.08 -- higher than 90.6% of US-listed equities with positive expected earnings growth.
  • MRTX's price/sales ratio is 108.19; that's higher than the P/S ratio of 97.78% of US stocks.
  • As for revenue growth, note that MRTX's revenue has grown 223.62% over the past 12 months; that beats the revenue growth of 97.62% of US companies in our set.
  • Stocks that are quantitatively similar to MRTX, based on their financial statements, market capitalization, and price volatility, are LIPO, GBIO, INMB, CLNN, and MTNB.
  • Visit MRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.mirati.com.

MRTX Valuation Summary

  • MRTX's EV/EBIT ratio is -5.4; this is 136.99% lower than that of the median Healthcare stock.
  • Over the past 127 months, MRTX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MRTX.

Stock Date P/S P/B P/E EV/EBIT
MRTX 2023-12-29 107.9 4.4 -5.7 -5.4
MRTX 2023-12-28 108.2 4.4 -5.7 -5.4
MRTX 2023-12-27 108.2 4.4 -5.7 -5.4
MRTX 2023-12-26 108.4 4.4 -5.7 -5.4
MRTX 2023-12-22 108.3 4.4 -5.7 -5.4
MRTX 2023-12-21 108.3 4.4 -5.7 -5.4

MRTX Growth Metrics

    Its 4 year price growth rate is now at 2178.05%.
  • Its 3 year revenue growth rate is now at 1447.97%.
  • Its 3 year price growth rate is now at 4.18%.
Over the past 33 months, MRTX's revenue has gone up $8,466,000.

The table below shows MRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 11.801 -579.755 -738.012
2022-06-30 78.163 -488.978 -644.505
2022-03-31 72.801 -438.853 -634.49
2021-12-31 72.092 -388.8 -581.784
2021-09-30 73.501 -327.236 -483.251
2021-06-30 13.132 -356.967 -490.533

MRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRTX has a Quality Grade of D, ranking ahead of 13.91% of graded US stocks.
  • MRTX's asset turnover comes in at 0.011 -- ranking 387th of 682 Pharmaceutical Products stocks.
  • CYRX, LUMO, and BDSI are the stocks whose asset turnover ratios are most correlated with MRTX.

The table below shows MRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.011 1 -0.668
2021-03-31 0.013 1 -0.658
2020-12-31 0.015 1 -0.750
2020-09-30 0.020 1 -0.781
2020-06-30 0.003 1 -0.737
2020-03-31 0.004 1 -0.765

MRTX Price Target

For more insight on analysts targets of MRTX, see our MRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $216.18 Average Broker Recommendation 1.56 (Moderate Buy)

Mirati Therapeutics, Inc. (MRTX) Company Bio


Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. The company was founded in 1995 and is based in San Diego, California.


MRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MRTX Latest Social Stream


Loading social stream, please wait...

View Full MRTX Social Stream

Latest MRTX News From Around the Web

Below are the latest news stories about MIRATI THERAPEUTICS INC that investors may wish to consider to help them evaluate MRTX as an investment opportunity.

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

Yahoo | December 27, 2023

Mirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 Shares

On December 18, 2023, Jamie Christensen, EVP & Chief Scientific Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), executed a sale of 2,387 shares in the company.

Yahoo | December 20, 2023

Insider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)

In a recent transaction on December 13, 2023, Benjamin Hickey, the Executive Vice President and Chief Commercial Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), sold 2,220 shares of the company.

Yahoo | December 15, 2023

Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges

(Bloomberg) -- Joe Lewis, the British billionaire behind one of the world’s biggest investing fortunes, continues to buy and sell stocks at the center of US insider-trading allegations against him.Most Read from BloombergJPMorgan Is in a Fight Over Its Client’s Lost $50 Million FortuneGoldman Trader Paid $100 Million Since 2020 Is Stepping DownArgentina’s Milei Devalues Peso by 54% in First Batch of Shock MeasuresNetflix Posts Viewer Data on Every Show, Film for First TimeRaimondo Vows ‘Stronges

Yahoo | December 12, 2023

3 Resilient Stocks with Massive Potential to Boost Your Wealth

These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life.

Rich Duprey on InvestorPlace | November 26, 2023

Read More 'MRTX' Stories Here

MRTX Price Returns

1-mo N/A
3-mo -0.09%
6-mo 34.76%
1-year 55.66%
3-year -63.06%
5-year -19.92%
YTD -0.09%
2023 29.66%
2022 -69.11%
2021 -33.21%
2020 70.45%
2019 203.77%

Continue Researching MRTX

Want to see what other sources are saying about Mirati Therapeutics Inc's financials and stock price? Try the links below:

Mirati Therapeutics Inc (MRTX) Stock Price | Nasdaq
Mirati Therapeutics Inc (MRTX) Stock Quote, History and News - Yahoo Finance
Mirati Therapeutics Inc (MRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!